Mikra Cellular Sciences, a Toronto, Canada-based biological sciences and consumer wellness company, raised $8.5M in funding.
Parent company Lifeist Wellness, Inc., made the investment.
The company intends to use the funds:
- to market its first product, CELLF™, engineered to increase cellular performance, as well as
- to continue product development.
Led by CEO Faraaz Jamal, Mikra is a biological sciences and consumer wellness company offering CELLF, a novel cellular therapeutic compound designed to help boost energy and mental focus on a cellular level. When ingested, CELLF seeks to counteract the effects of oxidative stress and damage to internal cellular systems and to bring the body back to homeostasis. Manufactured in a proprietary oxygen-deprived environment and only produced in small batches, CELLF works at a cellular level to help combat systemic fatigue, inflammation, and brain fog by promoting the creation of mitochondria, increasing their efficiency and removing the buildup of older, dysfunctional cells. In addition, the product uses a patented delivery mechanism that utilizes a transferrin glyco-protein that ensures the bioactive compounds are delivered to the best site of absorption within the body and directly into cells.
The company currently has a patent pending on CELLF’s formulation and mechanism-of-action and is currently conducting genomic pre-clinical trials to demonstrate the efficacy of the product at a genetic level with InVivo Biosystems. In addition, Mikra will continuously be improving CELLF with enhanced versions as the scientific results of trials yield further information. A scientific advisory group consisting of distinguished physicians and medical researchers will also be consulting on the product.